CXCL11 KO cell line available to order. Free of charge wild type control provided.
MCF7
Human
Breast
Liquid
Beta-R1, C-X-C motif chemokine 11, CXC11, CXL11_HUMAN, Chemokine (C-X-C motif) ligand 11, Chemokine C-X-C motif ligand 11, H174, I-TAC, IP-9, Interferon gamma-inducible protein 9, Interferon-inducible T-cell a chemoattractant I-TAC, Interferon-inducible T-cell alpha chemoattractant, MGC102770, SCYB11, SCYB9B, Small inducible cytokine subfamily B (Cys-X-Cys) member 11, Small inducible cytokine subfamily B (Cys-X-Cys) member 9B, Small inducible cytokine subfamily B, member 11, Small inducible cytokine subfamily B, member 9B, Small-inducible cytokine B11, b-R1
CXCL11 KO cell line available to order. Free of charge wild type control provided.
MCF7
Human
Breast
Liquid
Adenocarcinoma
CXCL11
Knockout
CRISPR technology
EU: 1 US: 1
Adherent
Female
Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.
1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.
MEM + 10% FBS + 0.01 mg/ml bovine insulin
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.
Dry Ice
-196°C
-196°C
Although we aim to provide customers with a homozygous clone, feasibility will be dependent on the biology of the protein. Should only heterozygous edits be achieved, you will be notified of the outcome and be asked to confirm whether the cell line is acceptable. All clones will be accompanied with DNA sequencing data, and the mutation description.
Recommended control: Human wild-type MCF7 cell line (Human wild-type MCF7 cell line ab288560). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
This supplementary information is collated from multiple sources and compiled automatically.
CXCL11 also known as I-TAC or Interferon-inducible T-cell alpha chemoattractant is a small cytokine belonging to the CXC chemokine family. It weighs around 8 to 11 kilodaltons. CXCL11 predominantly expresses itself in tissues such as the thymus spleen and peripheral blood leukocytes after stimulation with interferons. Its primary role is attracting activated T-cells especially those expressing CXCR3 receptor contributing to immune surveillance and response.
The chemokine plays an important role in immune system regulation and inflammation response. It attracts and activates leukocytes including T-cells and natural killer cells driving them to sites of inflammation and injury. CXCL11 is not part of a complex but interacts with other chemokines and cytokines to modulate immune responses. Its expression is upregulated in response to IFN-γ working synergistically with other chemokines like CXCL9 and CXCL10 in inflammatory environments.
CXCL11 is integral to the chemotaxis signaling pathway. It influences the migration and activation of immune cells by interacting with the CXCR3 receptor. This pathway shares involvement with proteins such as CXCL10 which also binds to CXCR3 enabling precise directionality and regulation of immune cell movement towards inflammation sites. Additionally CXCL11's participation in the inflammatory response pathway connects it to multiple cellular responses necessary for combating infections.
CXCL11 has been linked to autoimmune diseases and cancer. Its elevated expression is associated with conditions like multiple sclerosis where it may contribute to the pathological migration of immune cells into the central nervous system. In cancer CXCL11 can affect tumor microenvironments by recruiting immune cells with cytotoxic potential although this may also facilitate tumor progression in certain contexts. Proteins related to its disease association include CXCR3 and CXCL10 which together modulate various immunological outcomes in these diseases.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com